HOOKIPA Pharma (NASDAQ:HOOK) has announced the completion of enrollment for its Phase 1b trial evaluating HB-500 in patients with HIV.
The company stated that the study is comprised of two dose-escalation cohorts, with patients randomized to receive HB-500 or a placebo. The primary completion is expected in the second half of 2025.
Dan H. Barouch, MD, Ph.D., director of the Center of Vaccine and Virology Research, Beth Israel Deaconess Medical Center, and professor of medicine at Harvard Medical School, remarked, “HB-500 is designed to induce robust and durable immunity and is a key component of a combination strategy for a potential functional cure of HIV using novel mechanisms aimed at driving viral suppression, durable immunity and eradication of the pro-viral reservoir.”
